BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 38233752)

  • 1. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
    Liu W; Du Q; Mei T; Wang J; Huang D; Qin T
    BMC Cancer; 2024 Jan; 24(1):94. PubMed ID: 38233752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target.
    Li Y; Yang W; Liu C; Zhou S; Liu X; Zhang T; Wu L; Li X; Zhang J; Chang E
    Int Immunopharmacol; 2024 May; 132():111918. PubMed ID: 38537539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with
    Zhang YH; Liu XS; Gao Y; Yuan LL; Huang ZM; Zhang Y; Liu ZY; Yang Y; Liu XY; Ke CB; Pei ZJ
    Lung Cancer; 2024 Feb; 188():107449. PubMed ID: 38184958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of SFXN1 indicates poor prognosis and promotes tumor progression in lung adenocarcinoma.
    Chen L; Kang Y; Jiang Y; You J; Huang C; Xu X; Chen F
    Pathol Res Pract; 2022 Sep; 237():154031. PubMed ID: 35878532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
    Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
    BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
    Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L
    Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.
    Yang W; Chen K; Yu Q; Liao R; He H; Peng Y; Yang Z; Zhang X
    Cancer Med; 2023 Jul; 12(13):14820-14832. PubMed ID: 37162299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sideroflexin1 as a novel tumor marker independently predicts survival in lung adenocarcinoma.
    Chen Q; Wang R; Zhang J; Zhou L
    Transl Cancer Res; 2019 Aug; 8(4):1170-1178. PubMed ID: 35116859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
    Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
    Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Cell Death Index for Lung Adenocarcinoma: A Comprehensive Transcriptome-Based Analysis of Twelve Programmed Cell Death Pattern Genes.
    Chen F; Ma J; Hu S; Wu C; Chen S; Lin J
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):135. PubMed ID: 38682187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
    Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
    Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma.
    Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L
    BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
    Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
    PeerJ; 2023; 11():e16166. PubMed ID: 37790630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing.
    Zhang J; Liu X; Huang Z; Wu C; Zhang F; Han A; Stalin A; Lu S; Guo S; Huang J; Liu P; Shi R; Zhai Y; Chen M; Zhou W; Bai M; Wu J
    Comput Biol Med; 2023 Jan; 152():106460. PubMed ID: 36565482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.